Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

Bullboard Posts

Post by cornpieon Apr 22, 2010 4:04pm

441 Views

Post# 17021042

News............

iCo to present phase 1 iCo-007 trial study April 23
Ticker Symbol: C:ICO

iCo to present phase 1 iCo-007 trial study April 23

iCo Therapeutics Inc (C:ICO)
Shares Issued 41,057,301
Last Close 4/16/2010
.49
Thursday April 22 2010 - News Release

Mr. John Meekison reports

ICO-007 FOR DIFFUSE DIABETIC MACULAR EDEMA TO BE PRESENTED AT RETINAL PHYSICIAN SYMPOSIUM 2010

iCo Therapeutics Inc.'s phase I clinical trial study employing iCo-007 in diffuse diabetic macular edema (DME) will be highlighted in a presentation at the Retinal Physician Symposium 2010. iCo expects to release final results of its Phase I study later in Q2 2010.

The presentation will be made by David S. Boyer, MD and is currently planned for 9:00 am EST on Friday, April 23, 2010 at the Atlantis Paradise Island Resort in the Bahamas and will feature prominent scientists, clinicians and healthcare experts in retina care presenting new therapies and treatment strategies for retinal diseases. Dr. Boyer will highlight previously disclosed data from the iCo-007 Phase I open label study.

Dr. Boyer is a practising ophthalmologist who specializes in the treatment of diseases of the retina and vitreous. He is a Senior Partner at the Retina-Vitreous Associates Medical Group and a Clinical Associate Professor at the University of Southern California. He also has an extensive research background involving trials for age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis. Dr. Boyer has been on the advisory boards for Alcon, Novartis, Eyetech/Pfizer, Genentech, Neurotech and the Macular Degeneration Partnership and is a reviewer for several ophthalmology and diabetes medical publications including Archives of Ophthalmology, American Journal of Ophthalmology, Diabetes Care, and Ophthalmology.

About iCo-007

Designed and discovered by ISIS Pharmaceuticals Inc. (NASDAQ: ISIS), iCo-007 is a second-generation antisense drug targeting c-Raf kinase for the treatment of DME and diabetic retinopathy.

The primary endpoint of the Company's open label, dose escalating Phase I trial is safety, with visual acuity and measures of retinal thickness serving as secondary endpoints. Four U.S. clinical sites participated.

Bullboard Posts

Rig Count Soars as Utilization Surpasses Industry Averages